COVID-19 vaccine development has facilitated through unparalleled collaboration in the pharmaceutical industry and between governments. The geographic distribution of COVID-19 vaccine development puts North American entities having about 40% of the activity compared to 30% in Asia and Australia, 26% in Europe, and a few projects in South America and Africa
The safety requirements for COVID-19 vaccines are the same as for any other vaccine and will not be lowered in the context of the pandemic. After development, the vaccines will continue to be carefully monitored for safety and effectiveness
Title : Nanomaterial-mediated systemically administered m-RNA-based gene therapy directed exclusively to cancer, present successes and future prospects
A C Matin, Stanford University, United States
Title : Personalized and precision medicine (PPM) as a unique healthcare model to be set up via biodesign, bio- and chemical engineering, translational applications, and upgraded business modeling to secure the human healthcare and biosafety
Sergey Suchkov, The Russian University of Medicine and Russian Academy of Natural Science-Moscow, Russian Federation
Title : Clinical pharmacology of aprocitentan (an endothelin receptor antagonist) – The most recent quality progress in treatment of resistant hypertension
Miroslav Radenkovic, University of Belgrade, Serbia
Title : Clinical decision making in advanced and metastatic breast cancer cases between PARP inhibitors and CDK4/6 inhibitors
Priya Hays, Hays Documentation Specialists, LLC, United States
Title : Emerging formulation and delivery applications of vitamin E TPGS
Andreas M Papas, Antares Health Products, United States
Title : Novel nano drug platform for pharmacologically inducing therapeutic hypothermia (TH) after traumatic brain injury (TBI)
Jorge David Tovar Castro, University of Miami Miller School of Medicine, United States
Title : Global drug development - Trends, challenges and opportunities
Gurpreet Singh, IQVIA, United Kingdom
Title : Drug design for the development of long-acting injectables
Thomas Ullrich, Novartis Biomedical Research, Switzerland
Title : Synthesis and properties of new unique heterocyclic systems: Pyrido[3'',2'':4',5']furo(thieno)[3',2':4,5]pyrimido[2,1-f][1,2,4]triazines
Anush, National Academy of Sciences of the Republic of Armenia, Armenia
Title : Development and evaluation of prolonged-release dutasteride transdermal delivery system
Shereen M. Assaf, Jordan University of Science and Technology, Jordan